anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The use of TXA in orthopedic trauma patients is an area of current research interest. A 2010 prospective randomized, controlled trial of perioperative TXA demonstrated reduction in transfusion requirements for intertrochanteric hip fractures treated with short, cephalomedullary nails. This was clinically, though not statistically, significant. Investigators recently conducted a randomized, controlled trial at this institution to evaluated the use of TXA in patients with femoral neck fractures treated with hemiarthroplasty or total hip arthroplasty and found clinically, albeit not statistically, significant reduction in transfusion requirement (accepted for publication). Perhaps tempering the effect seen with perioperative administration of TXA is the blood loss that occurs prior to surgery, the so-called "hidden" blood loss that can be as substantial as 1/3 of total blood loss from a hip fracture. This raises the question whether administration of tranexamic acid at the time of initial presentation after fracture could improve the perioperative care of these patients by decreasing the proportion of patients requiring transfusion and decreasing total blood loss.
Cyanocobalamin Nasal Spray is a nasal spray available in a dosage strength of 500 mcg cyanocobalamin/0.1 mL (per actuation). It is supplied in boxes of 4 single-use nasal spray devices and a package insert (NDC 43386-237-70).

Protect from light. Keep covered in carton until ready to use. Store upright at controlled room temperature 15°C to 30°C (59°F to 86°F). Protect from freezing.
Administer irinotecan hydrochloride injection as a 90-minute intravenous infusion. The currently recommended regimens are shown in Table 3.

A reduction in the starting dose by one dose level of irinotecan hydrochloride injection may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients.

Dose Modifications 

Based on recommended dose-levels described in Table 3, Single-Agent Regimens of irinotecan hydrochloride injection and Dose Modifications, subsequent doses should be adjusted as suggested in Table 4, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity.
PURPOSE:A composition useful as toothpaste, filler kiss paste, etc. having proper polishing properties by itself, showing improved luster imparting effect on the teeth, having proper polishing power, cleaning power, obtained by blending an oral cavity composition with anhydrous alpha-alumina having a specific crystal size. CONSTITUTION:An oral cavity composition is blended with alpha-alumina anhydride having 0.1-2.5mum average crystal size. alpha-Alumina comprising particles having 0.1-4.5mum secondary aggregation particle diameters, containing no particles having >=5mum secondary aggregation particle diameter, is preferably used as the alpha-alumina anhydride. The composition for oral cavity obtained reduces surely scratch, has no feeling of roughness to the tongue, and has good feeling in use. An amount of alpha-alumina anhydride blended is 0.1-60wt% based on total amount of the composition, and especially 0.1-10wt% when it is mixed with another polishing material. EFFECT:Even if the alpha-alumina anhydride is mixed with a polishing agent having high polishing power such as Al(OH)3, calcium hydrogenphosphate containing no hydrate, polishing silica, etc., it can make the teeth smooth without damaging them.
Behavioral lifestyle intervention: Participants (N=40) will be randomized to the mHealth+ group Intervention group (Group A; n=20)and mHealth+ individual intervention group (Group B; n=20) group using a randomization table. (1) The mHealth+ group Intervention group (Group A) will receive a modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity. This comprises ten group sessions for lifestyle intervention in 6-months. The group will receive three weekly classes in the first month and then bi-weekly classes for month 2-3, and three monthly session in month four, five, and six. The frequency and layout of these classes will allow participants to master new skills gradually, then eventually wean off, and adopt the modified lifestyle as the part of their daily lives. (2) The mHealth+ individual intervention group (Group B) will receive an abbreviated behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity in one face-to-face individual session at the beginning of the study. In addition, participants will receive self-study materials, from Look Ahead modules, and a monthly follow-up phone calls for the duration of the study (6-months). The goal for these follow up phone calls are to assess understanding of the modules, to promote continued engagement with the study material, and to provide clarification on materials as needed. Participants in the mHealth+ group Intervention group (Group A) and mHealth+ individual intervention group (Group B will receive instruction on how to download an app to help them record their diet and physical activity at the beginning of the study.

Fitbit offers a simple, easy-to-use tool for tracking food and physical activity. It helps set daily calorie budget, and set and work towards goals for nutrient intake, weight loss, exercise, and more. https://www.fitbit.com/inspire 04.12.20: Due to SARS-CoV2 (COVID-19) and social distancing order, the study team are adding hemoglobin Hba1c home test.
The cerebellum is important for coordination of movement and for motor learning. No medications systematically improve cerebellar ataxia, and little is known about the effectiveness of rehabilitation exercises, which are often the only treatment option. Here, we ask whether a person's ability to adapt (i.e. short term motor learning) predicts their ability to benefit from physical therapy exercises. This pilot-clinical trial will test a subject's ability to adaptively learn a new walking pattern in a single session, and then any improvement of walking and balance over a 13 week time period during which they participate in a specialized home exercise training program. Our prediction is that those individuals with some preserved adaptive learning ability will be the best rehabilitation candidates.
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for patients with acute ST-segment elevation myocardial infarction (STEMI). Additional antithrombotic therapy prior or during intervention plays an important role in the short- and long-term outcomes after PPCI. Oral antiplatelet therapy including a platelet P2Y12 receptor inhibitors is a cornerstone of antithrombotic treatment in patients with acute coronary syndromes. Prasugrel and Ticagrelor have been shown to be superior to Clopidogrel in patients with STEMI in reduction of ischemic complication without any increase in the bleeding risk and with a significant reduction in the stent thrombosis rate. Nevertheless, in STEMI patients, pharmacodynamic studies showed prasugrel and ticagrelor oral loading dose (LD) provided a suboptimal platelet inhibition in the first hours after LD, and at least 4 hours are required to achieve and effective platelet aggregation inhibition in the majority of patients, in part due to slowed gut motility caused by morphine use. Orodispersible tablet (ODT) is a different tablet formulation that disperses upon contact with the moist mucosal surfaces of the oral cavity and quickly release its components before swallowing; thus local drug dissolution and absorption as well as onset of clinical effect can be obtained conveniently easily and quickly by bypassing gastrointestinal tract. Recently, Ticagrelor 90 mg ODT has become available and bioequivalence studies on healthy volunteers documented its effectiveness with consequent approval by European Medicine Agency of this formulation which is currently available on the market. Thus, the aim of the present study is to evaluate the superiority in platelet inhibition with 180 mg Ticagrelor loading dose (LD) administered as ODTs as compared with standard formulation, among patients with STEMI or very high-risk NSTEMI undergoing immediate PCI. Primary objective consists in evaluating platelet reactivity 1 hour after Ticagrelor loading dose by VerifyNow test.
BACKGROUND: Chronic Kidney Disease [CKD] affects individuals of different age groups worldwide. Moreover, CKD is associated with several risk factors, including obesity, lifestyle, and hypertension, which are common in the Middle East. Ultrasonography is the examination of choice for CKD. In recent years, Shear Wave Elastography [SWE] has developed through the continued development of ultrasound and received substantial attention ;therefore, it can be used to measure tissue stiffness. The study aimed to use point Shear Wave Elastography [p-SWE] to determine the correlation between diabetes and cortical renal thickness in detecting pathologies.
METHODS: This study was performed at the King Abdul-Aziz University Hospital. We examined 61 patients who underwent SWE. The patients were classified into two groups based on the presence or absence of type 2 Diabetes Mellitus [DM].
RESULTS: The results showed that there was a significant correlation between cortical stiffness and DM duration [p<0.005]. In addition, there was a negative correlation between cortical stiffness and cortical thickness [p=0.147] in patients with DM. Moreover, the eGFR decreased with an increase in cortical stiffness [p=0.499]. The cortical thickness in patients with and without DM was 0.750 ± 0.2 kPa and 0.788 ± 0.4 kPa, respectively. The kidney stiffness in patients with DM and control patients was 8.5 ± 8.6 cm and 14.0 ± 25.16 cm, respectively.
CONCLUSION: This study showed that kidney p-SWE measurements were reliable. Therefore, further studies assessing kidney stiffness in patients with and without people with diabetes are recommended.
Disclosed are methods of treating an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP. Disclosed are methods of preventing rupture of an aneurysm comprising administering to a subject having an aneurysm a composition comprising a SELP, wherein the SELP is present in the aneurysm and prevents rupture. Also disclosed are methods of embolizing an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising SEEP. Disclosed are methods of treating AVM in a subject comprising administering to the subject a composition comprising a SELP. In some aspects, the SELP embolizes an abnormal blood vessel in the AVM. Disclosed are methods of embolizing an AVM in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP, wherein the SELP embolizes an abnormal blood vessel in the AVM.
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of immunology and biotechnology. Presented are isolated artificial or recombinant antibody or its functional part, capable of specific binding F-antigen of respiratory-syncytial virus, which include: variable sequence of heavy chain, containing CDR1 NYIIN (SEQ ID NO:1), CDR2 GIIPVLGTVHYAPKFQG (SEQ ID NO:2), CDR3 ETALVVSTTYLPHYFDN (SEQ ID NO:3), and variable sequence of light chain, containing CDR1 QASQDIVNYLN (SEQ ID NO:4), CDR2 VASNLET (SEQ ID NO:5), CDR3 QQYDNLP (SEQ ID NO:6); as well as nucleotide sequence coding said antibody. Described is isolated mammalian cell, including said nucleic acid, where said cell expresses said nucleic sequence. Disclosed is method of obtaining antibody or its functional part, including: cultivation of said cell in vitro; and obtaining antibody or its functional fragment, produced by said cell. Described is composition for treatment or prevention of RSV-associated disorder, or preventing or counteracting unfavourable effect of RSV infection on humans, including therapeutically efficient quantity of said antibody or its functional part and pharmaceutically acceptable carrier, solvent or excipient. Claimed is application of said antibody or coding it nucleic sequence for obtaining medication for treatment or prevention of RSV-associated disorder, or preventing or counteracting unfavourable effect of RSV infection on humans.EFFECT: invention makes it possible to extend arsenal of means for treatment or prevention of RSV-associated disorders.22 cl, 16 dwg, 3 tbl, 5 ex
Phase 1b randomized, double-blind, placebo-controlled dose escalation trial of sedation regimens in critically ill children. Testing the hypothesis of mean daily fentanyl dose through day 7 of mechanical ventilation will be reduced by ≥25% by the addition of dexmedetomidine to fentanyl therapy. This trial will involve multiple clinical sites. Randomization will occur by individual and investigators will be blinded to study/treatment arm. The statistical analysis will account for center effects, participant characteristics (including post-surgical state), and changes over time to minimize bias. In addition, PIs and study coordinators will undergo training to standardize assessment procedures. The study will randomize participants to receive placebo (fentanyl standard of care) titrated to sedation+saline placebo (bolus+infusion) or one of the following 3 Dexmedetomidine treatment arms in a sequential cohort fashion: Cohort 1: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2 mcg/kg/hr infusion); Cohort 2: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion); and, Cohort 3: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion).

An interim analysis is planned for this trial.
Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.
A member of the research personnel helps the participants install Netflix, Spotify, and Skype applications on their computers if they wish to do so. Participants will be given subscriptions to each application and usernames for access on days -5 to 10.
While viruses are considered the most common infectious triggers for cytokine storm syndromes (CSS), a growing list of bacterial pathogens, particularly intracellular organisms, have been frequently reported to be associated with this syndrome. Both familial and sporadic cases of CSS are often precipitated by acute infections. It is also important to note that an underlying precipitating infection might not be clinically obvious as the CSS clinical picture can mimic an infectious process or an overwhelming septicemia. It is important to detect such an underlying treatable condition. In addition, infections can also be acquired during the course of CSS due to the concurrent immune suppression with treatment. Optimal CSS outcomes require treating bacterial infections when recognized.CSS should always be suspected in patients presenting with a sepsis-like or multi-organ dysfunction picture. There are many criteria proposed to diagnose CSS in general, with HLH-2004 being the most commonly used. Alternatively, criteria have been proposed for CSS occurring in specific underlying conditions such as systemic lupus erythematosus (SLE) or systemic juvenile idiopathic arthritis (sJIA). However, waiting for many of these criteria to be fulfilled could lead to significant delay in diagnosis, and the physician needs a high index of suspicion for CSS in critically ill febrile hospitalized patients in order to properly recognize the condition. Thus, there should be diagnostic equipoise between CSS and infections, including bacterial, in this population. In this chapter, we discuss the more common bacterial precipitants of CSS with many of the cases being discussed in the pediatric age group.
FIELD: cosmetology. SUBSTANCE: coloring composition for keratin fibers, particularly, hair contains, in acceptable for coloring medium, direct cation coloring. Besides, composition contains silicon selected from aminated silicon, polyoxyalkylated silicons, pure silicon rubbers and silicon resins. The invention also deals with methods and a set for coloring using said composition. EFFECT: intensive, low-selective coloring stable to aggressive action. 33 cl
<P>PROBLEM TO BE SOLVED: To provide a liquid base agent for fragrant cosmetics that exhibits good dispersion stability and has low turbidity and good stability with time, where the base agent or a fragrant cosmetic composition comprising the same exhibits sufficient lubricity and does not make the hair or the skin sticky.  <P>SOLUTION: The liquid base agent for fragrant cosmetics comprises as essential ingredients (A)-(C) below and contains 0.1-10 wt.% of (B) based on the weight of the liquid base agent and has a turbidity (JIS K0101-1998.9.4 integrating sphere turbidity) at 25°C of at most 20 mg/L. (A) An organic dispersing medium which is liquid at 25°C. (B) A bivalent or trivalent metal salt of an 8-24C higher fatty acid. (C) A dispersant comprised of a specific organic acid (salt) and/or a nonionic surfactant.  <P>COPYRIGHT: (C)2008,JPO&INPIT
INTRODUCTION: Venous thromboembolism (VTE) is a major concern following total knee arthroplasty (TKA). The optimal pharmacological prophylaxis remains, however, controversial. The present investigation compared several non-vitamin K antagonist oral anticoagulants commonly employed as VTE prophylaxis following TKA. A Bayesian network meta-analysis was conducted to compare apixaban, aspirin, dabigatran, edoxaban, enoxaparin, fondaparinux, and rivaroxaban. The outcomes of interest were to compare the rate of deep venous thrombosis (DVT), pulmonary embolism (PE), and major and minor haemorrhages.
METHODS: This study was conducted according to the PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions. In March 2024, PubMed, Web of Science, and Google Scholar were accessed with no time constraints. All randomised controlled trials (RCTs) comparing two or more drugs for the prevention of VTE following TKA were considered for inclusion.
RESULTS: Data from 29,678 patients were collected. Of them, 67% (19,884 of 29,678 patients) were women. The mean age of the patients was 66.8 ± 2.8 years, and the mean BMI was 29.2 ± 1.5 kg/m2. There was comparability in age, sex, and BMI at baseline. Apixaban 5 mg, dabigatran 220 mg, and rivaroxaban 10 mg were the most effective in reducing the rate of DVT. Apixaban 5 mg, enoxaparin 60 mg, and rivaroxaban 40 mg were the most effective in reducing the rate of PE. Apixaban 5 mg, rivaroxaban 10 mg, and apixaban 10 mg were associated with the lowest rate of major haemorrhages. Apixaban 5 mg and 20 mg, and dabigatran 220 mg were associated with the lowest rate of minor haemorrhages.
CONCLUSION: Administration of apixaban 5 mg demonstrated the best balance between VTE prevention and haemorrhage control following TKA.
LEVEL OF EVIDENCE: Level I, network meta-analysis of RCTs.
Gallstone disease (GD) is a common gastrointestinal disease. Although traditional diagnostic techniques, such as ultrasonography, CT, and MRI, detect gallstones, they have some limitations, including high cost and potential inaccuracies in certain populations. This study proposes a machine learning-based prediction model for gallstone disease using bioimpedance and laboratory data. A dataset of 319 samples, comprising161 gallstone patients and 158 healthy controls, was curated. The dataset comprised 38 attributes of the participants, including age, weight, height, blood test results, and bioimpedance data, and it contributed to the literature on gallstones as a new dataset. State-of-the-art machine learning techniques were performed on the dataset to detect gallstones. The experimental results showed that vitamin D, C-reactive protein (CRP) level, total body water, and lean mass are crucial features, and the gradient boosting technique achieved the highest accuracy (85.42%) in predicting gallstones. The proposed technique offers a viable alternative to conventional imaging techniques for early prediction of gallstone disease.
PROBLEM TO BE SOLVED: To obtain a skin lotion which shows an excellent preventive or reforming effect on dermal aging, possesses a high safety and is useful for fundamental cosmetics, makeup cosmetics, hair cosmetics or the like by including an extract from Boswellia Serrata. SOLUTION: This skin lotion is obtained by including an extract from Boswellia Serrata preferably in a proportion of 0.001-10.0 wt.% based on the whole weight as the dry substance. The above extract is obtained by immersing or refluxing the bark of the above plant together with an extracting solvent, e.g. ethanol or the like, followed by filtration and concentration. As the dosage form of this preparation, ointments, creams, milky lotions or the like are illustrated. This preparation exerts an excellent inhibitory effect against collagenase activity, prevents collagen from decomposing caused by collagenase and can sustain elastic skins having no wrinkles and bags.
PURPOSE: A composition for a medicine, food, or a beverage is provided to prevent telangiectasia on the face, neck, hands, and/or shoulders of a consumer by comprising a H2 histamine receptor antagonist. CONSTITUTION: A composition for a medicine for suppressing telangiectasia due to alcohol consumption comprises cimetidine and a carrier which is pharmaceutically acceptable. The composition is injected 2-60 minutes before alcohol consumption. The composition for food or a beverage for suppressing telangiectasia due to alcohol consumption comprises cimtidine, an excipient, and an additive. The composition is injected 2-60 minutes before drinking alcohol. [Reference numerals] (AA) Front; (BB) Back
The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.